Company Description
DMK Pharmaceuticals Corporation, a clinical stage neuro-biotechnology company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory diseases.
The company's lead clinical stage product candidate, DPI-125, which is indicated for the treatment of opioid use disorder.
Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose.
The company was formerly known as Adamis Pharmaceuticals Corporation and changed its name to DMK Pharmaceuticals Corporation in September 2023.
The company is headquartered in San Diego, California. On February 2, 2024, DMK Pharmaceuticals Corporation, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
| Country | United States |
| Founded | 2006 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 11 |
| CEO | Dennis Carlo |
Contact Details
Address: 11682 El Camino Real, Suite 300 San Diego, California 92130 United States | |
| Phone | (858) 997-2400 |
Stock Details
| Ticker Symbol | DMKPQ |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000887247 |
| Employer ID | 82-0429727 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Seth Abraham Cohen | Chief Financial Officer |
| John W. Dorbin Jr. | General Counsel Corporate Secretary |
| Eddie Wabern Glover | Chief Executive Officer of US Compounding Inc |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 21, 2024 | 25-NSE | Filing |
| Feb 7, 2024 | 8-K | Current Report |
| Feb 6, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 5, 2024 | 8-K | Current Report |
| Jan 31, 2024 | 8-K | Current Report |
| Jan 23, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jan 23, 2024 | 8-K | Current Report |
| Jan 3, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jan 3, 2024 | 8-K | Current Report |
| Jan 3, 2024 | 8-K | Current Report |